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Abstract HIV is a devastating worldwide epidemic that has
had substantial social and economic impacts throughout the
globe. Due to the presence of a small pool of latently infected
cells that persists during antiretroviral therapy (ART), HIV is
not curable. Because of the high cost of ART and the lack of
reliable accessibility across the globe, life-long ART is unfor-
tunately not a feasible solution for the epidemic. Therefore,
new strategies need to be developed and implemented to ad-
dress HIV-1 infection. Several approaches toward this end are
currently under investigation (Ebina et al. in Sci Rep 3:2510,
2013; Archin et al. in Nature 487:482–5, 2012; Elliott et al. in
PLoS Pathog 10:e1004473, 2014; Rasmussen et al. in Lancet
HIV 1:e13–e21, 2014; Tebas et al. in N Engl J Med 370:901–
10, 2014; Archin et al. in Nat Rev Microbiol 12:750–64,
2014; Barton et al. in PLoS One 9:e102684, 2014; Sogaard
et al. in PLoS Pathog 11:e1005142, 2015). Initial studies have
proven promising, but have highlighted the need for sensitive
and accurate assays to detect changes in very low concentra-
tions of virus to allow confident interpretation of the success of
curative approaches. This review will focus on assays that are
currently available and the advantages and limitations of each.
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Introduction
Antiretroviral therapy (ART) effectively reduces the amount
of HIV-1 in infected individuals to levels that are undetectable
by most clinical measures. However, the small reservoir of
virus that is able to persist has the capacity to develop into a
full HIV-1 infection if ART is stopped [1]. Therefore, this
reservoir has important implications for infected individuals
[2]. To cure HIV-1, gene therapy, bone marrow transplant, and
combined pharmacological and immune therapy are some of
the most well-known methods that are being actively ex-
plored. An accurate and sensitive measure of the latent reser-
voir is needed to measure outcomes of these studies [3, 4,
5••,6••,7–9,10••]. The persistent reservoir of latent HIV-1 that
remains during effective long-term therapy has been intensely
studied, and several important features of the reservoir have
been elucidated. The most well-studied reservoir exists in the
resting CD4-positive T cells of the peripheral blood and in the
intestine [11, 12]. Most measures of the persistent pool of
HIV-1 focus on the peripheral blood as a surrogate marker
of other reservoirs due to its accessibility. However, alternate
reservoirs of persistent HIV-1 have been detected in the lymph
nodes, seminal fluid, and cerebral spinal fluid [11, 13]. The
majority of infected cells contain only a single HIV-1
integrant, meaning that measurement of integrated cell-
associated DNA generally correlates with the number of cells
that are infected with HIV [14, 15••]. Once ART therapy is
initiated, no viral evolution is detected indicating that there is
no ongoing viral replication when ART adherence is high
[16]. However, while HIV-1 does not replicate, the pool of
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latently infected cells can maintain or expand through cell
proliferation of infected cells [17]. Therefore, while the persis-
tent reservoir is not expanded through ongoing HIV-1 replica-
tion, due to the presence of long-lived cells and cell proliferation,
it can be maintained over time. These important studies have
paved the way for future assays to measure the latent reservoir
and allow informed evaluation of the assays in use. To date,
several innovative assays that measure various aspects of the
latent reservoir have been developed, and these assays are being
used to direct clinical decisions regarding continuation of ART.
To fully understand the difficulty of developing an effec-
tive and efficient measure of the latent reservoir, it is important
to define what an ideal assay would include. The first and
most important feature, but possibly the most difficult, would
be to measure the entire reservoir of replication competent
virus and nothing more. Specifically, the assay would need
to quantify replication competent HIV-1 without including
defective virus. The majority of HIV-1 proviral genomes that
persist in HIV-1-infected individuals on long-term suppressive
therapy are defective in that they contain premature stop co-
dons and/or large internal deletions and insertions [18•]. It is
important to distinguish between defective and replication
competent virus because in theory, HIV-1-infected individuals
could remain off ART indefinitely if all replication competent
viruses are eliminated while cells containing defective virus
remain. However, defective virus that is not replication com-
petent, but makes partial viral proteins, can cause persistent
immune activation. Persistent immune activation also has
long-term deleterious effects, and therefore, sterilizing strate-
gies that remove all HIV-1, such as gene therapy, may ulti-
mately prove to be an optimal therapeutic choice.
Second, an ideal assay would be able to provide an accurate
assessment of howmuch replication competent virus is present
in tissue compartments that are not necessarily sampled. Due to
the limited amount of interventions a participant can reason-
ably be expected to endure to efficiently deploy an assay across
the many health-care systems around the globe, an ideal assay
would require only a single blood sample, but would need to
be able to accurately predict the levels of HIV-1 in tissue com-
partments such as the intestine, the lymph nodes, the nervous
system, and yet undefined populations. Third, an ideal assay
would have very strong confidence in a negative result as false
negatives would have devastating effects on the patient. While
this may seem like a difficult task at first glance, combining
current methods with theoretical modeling may provide suffi-
cient data to make initial predictions while more sensitive and
deployable methods are developed.
Assays to Measure the Persistent Reservoir
The first group of assays that is going to be discussed measures
virus that is replication competent and can infect cells in
culture. Collectively, these assays use viral outgrowth to mea-
sure the latent reservoir. So far, three assays have been devel-
oped. As a group, viral outgrowth assays are very promising
because they are the only class of assays that detect only repli-
cation competent virus. However, they share a common limita-
tion in that they are not necessarily able to detect all replication
competent viruses and, if used as the sole predictor of reservoir
size could, lead to premature discontinuation of ART [18•].
The quantitative viral outgrowth assay (QVOA) is current-
ly the gold standard for detection of the HIV-1 latent reservoir
[1, 19, 20]. In this assay, blood or leukopheresis product is
obtained from HIV-1-infected individuals, and CD4+ T cells
are isolated by negative selection. The CD4+ Tcells are plated
in limiting dilution to allow quantification and are stimulated
with PHA and irradiated lymphoblasts from a non-infected
donor to induce viral outgrowth. Then, CD8+ depleted lym-
phoblasts are added to amplify the virus that is released. After
several weeks of incubation, the wells that contained replica-
tion competent HIV-1 are detected by ELISA for HIV-1 p24
antigen. QVOA has many advantages with the most pro-
nounced being its ability to only detect replication competent
virus. However, it is also costly, time-consuming, and
resource-intensive; requires large samples from the study par-
ticipants; and does not detect all replication competent virus
[18•, 21]. Several variants of this assay have been developed
to reduce the cost and length of QVOA including the use of
MOLT-4/CCR5 cells in place of donor cells for viral expan-
sion, which decreases the amount of required culture time
[22]. This assay also reduces the total time by detecting
HIV-1 RNA with quantitative PCR (qPCR) instead of using
ELISA. The initial steps of the viral outgrowth assay are
followed; however, culturing is stopped after only three or
seven days, and viral RNA is detected by qPCR [22].
An alternative to the traditional QVOAwas recently proposed
by Swanstrom et al. in which the maximum number of CD4+ T
cells (ten million) is cultured in each well, and then, the positive
wells are sequenced using ultra-deep sequencing to determine
the number of unique viruses that replicated in each well. This
approach allows more cells to be cultured with fewer resources.
One minor limitation to this assay is that it is less accurate in
participants treated during acute infection due to a lack of genetic
diversity, which is necessary to be able to quantitate the number
of individual founder viruses were present in each well [23].
Recently, another variant of the viral outgrowth assay using
humanized mice (MVOA) was developed. In this assay, CD4+
T cells or PBMCs from HIV-infected individuals are injected
into Nod.CgPrkdcscidIl2rgTm1Wj1/SzJ (NSG) mice. Viral loads
are thenmonitored using real-time PCR for HIV1 RNA. Up to
60 million cells can be injected per mouse, and multiple mice
can be used per HIV-1-infected individual increasing the num-
ber of cells that can be screened. In the trials that have been
run so far, HIV-1 was detected in mice injected with cells from
participants on ART and elite controllers with viral loads less
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than 50 copies per milliliter. HIV-1 RNAwas detected in the
plasma of the humanized mice after xenograft with PBMCs
from five participants who were on effective long-term ART
and from six elite controllers. MVOA also has the potential to
screen cells from alternate tissue reservoirs such as the gut-
associated lymphoid tissue and lymph nodes. This assay has a
higher sensitivity than the QVOA but is not quantitative and is
thus limited to determining whether the participant still har-
bors replication competent virus [24]. MVOA is a very pow-
erful tool for determining whether replication competent virus
is present in large amounts of cells. However, the MVOA
assay would be less informative in detecting fold reductions
in the latent reservoir that could potentially lead to long pe-
riods of HIV-1 remission.
Residual viremia can be detected in a significant portion of
HIV-1-infected individuals on effective therapy using very
sensitive methods [25, 26]. The single-copy assay (SCA) is
a sensitive real-time RT-PCR-based assay that can measure
down to one copy of viral RNA per milliliter of plasma
[25–29]. SCA uses primers directed at the highly conserved
regions of gag and integrase. Comparison to serial dilutions of
a standard is used to quantify the total amount of viral RNA. In
addition, an internal standard (avian retrovirus) is added to all
plasma samples to monitor the extraction and measurement of
low-level viral RNA. SCA is more sensitive than any of the
clinical detection methods that are currently available.
Commercial assays including the Roche Ampliprep [30] and
Abbot real time HIV-1 assays can also be used to measure
HIV-1 RNA in the plasma. These assays are much less sensi-
tive than the SCA with lower limits of 20 or 40 copies per
milliliter, respectively. Assays that measure plasma RNA do
not detect latent virus that is not producing transcripts and do
not determine whether the virus is replication competent.
Furthermore, because they use specific primers, some propor-
tion of virus may not be detected due to mutation or viral
variation. Despite these limitations, the single-copy assay
can often detect plasma RNA in individuals on ART.
During the HIV-1 replication cycle, several nucleic acid
forms of the viral genome are created including full-length
viral RNA, 2-LTR DNA circles, integrated DNA, as well as
multiply spliced and incompletely spliced mRNA.
Quantitative PCR assays can be used to distinguish between
each form or to measure total RNA or DNA according to the
amplification region [31]. It is important to carefully select
which region is targeted by these assays. Short abortive tran-
scripts from the HIV-1 LTR can be detected in the absence of
full transcription due to limitations of the elongation machin-
ery [32]. Additionally, regions such as env are known to be
highly diverse, which makes false negatives due to primer
mismatch more likely. Protein regions such as tat and
integrase are highly conserved and are therefore less likely
to produce false negative results. When measuring RNA, it
is important to keep in mind that fully spliced RNAs are
produced early in infection and encode rev, which is required
for nuclear export and translation of multiply spliced and
unspliced HIV-1 RNA. Furthermore, HIV-1 integrated into
an exon of a gene can be translated as a full-length genome
within that gene without the potential to be translated into
functional proteins or be incorporated into a virion as a viral
genome [2, 11]. Additionally, integrated DNA species that
contain mutations rendering them defective may still produce
RNAs. Defective integrated HIV-1 genomes can be propagat-
ed through cellular proliferation due to antigenic or homeo-
static proliferation. Multiply spliced RNAs are highly
expressed during early infection peaking at five hours while
unspliced RNAs dominate at later stages of infection [33].
Furthermore, multi-spliced RNAs are generally undetectable
in individuals on ART while unspliced RNA can be detected
at a very low level [32]. A ratio of the two species can be used
to provide an idea of whether new infections are occurring
[32, 34, 35]. Therefore, detection of each type of viral RNA
or DNA provides an independent measure with varying
amounts of reliability regarding its ability to predict howmuch
replication competent HIV-1 is present [18•, 36].
The PCR-based assays are the most flexible group of assays
available in that they are able to differentiate between many
different stages of the viral life cycle [11, 37–41]. Additionally,
these assays are very sensitive and specific. Most assays in use
rely on quantitative real-time PCR, while some of the newer
methods have moved to digital droplet PCR (ddPCR) to in-
crease sensitivity [42]. Measurement of total DNA includes
both integrated and 2-LTR circle forms of the HIV-1 genome
[43, 44]. While the longevity of 2-LTR circles is controversial,
accurate measures of integrated HIV-1 genomes can be mea-
sured using Alu PCR [29, 45–47]. Alu PCR is a method that
takes advantage of very common Alu elements that are present
in the human genome along with HIV-1-specific primers that
bind to the gag region. Together, these primer sets are used to
detect integrated HIV-1 DNA in cells [48–50].
The tat/rev induced limiting dilution assay (TILDA) mea-
sures inducible multiply spliced HIV-1 RNA [51]. This ap-
proach is a better predictor of the actual reservoir size than
other PCR-based methods because it measures RNAs pro-
duced in response to stimulation with PMA indicating that
the proviral LTR is intact. Furthermore, the primers used for
TILDA are specific to the tat/rev region, which is the most
commonly deleted region in proviruses. In one study, TILDA
predicted a latent reservoir that was 48 times higher than that
predicted by QVOA and 6–27 times lower than that predicted
by PCR-based assays, supporting its ability to measure a larger
proportion of the latent reservoir thanQVOAwhile beingmore
discriminating than traditional PCR-based approaches [51].
While highly sensitive, none of the PCR-based assays are
able to fully differentiate between replication competent and
defective virus, meaning that for the most part, they may over
estimate the total latent reservoir. Additionally, due to the
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capricious nature of the HIV-1 genome, even primers targeting
the most conserved regions may miss some sequences.
Moreover, many of the primers used for PCR assays are some-
what subtype-specific, and therefore, knowledge of the sub-
type may be required for optimal implementation. Despite
these drawbacks, PCR-based assays are some of the least ex-
pensive and most transferable assays available. Furthermore,
PCR assays may be able to be combined with sequencing data
to estimate the percent of detected HIV that is defective and
provide a more accurate measure of the latent reservoir.
Measures of the immune response can also be used as bio-
markers to predict HIV-1-free remission. Several different
measures of immune activity are available including HIV-1
antibody detection, response of T cells to HIV-1 antigen, and
markers of activated T cells. To measure HIV-1-specific anti-
bodies, the most common method in use is ELISA. ELISA
can detect both the avidity and quantity of HIV-1 antibodies
and can be used to predict whether the participant is acutely or
chronically infectedwithHIV [52]. Two recent studies follow-
ing participants with stem cell transplants both showed de-
clines in HIV-1 antibodies over time [53••, 54••]. However,
this decline is associated with a continued remission for one
individual while it was only associated with a delay in viral
rebound for the other two individuals. Therefore, while the
levels and avidity of HIV-1 antibodies can be used as a pre-
dictor of HIV-1 levels, this method may need to be supple-
mented with additional measures. The luciferase immunopre-
cipitation system, which uses chimeric Renilla luciferase and
pathogen-specific antigens to quantitate HIV-1-specific anti-
bodies, demonstrated that the levels of antibodies to p24 and
gp41 were significantly lower in a participant that has not
rebounded than in elite controllers who control viremia with-
out ART and HIV-infected individuals on or not on ART.
Therefore, the levels of p24- and gp41-specific antibodies
may be a surrogate biomarker of reservoir size [55].
HIV-specific Tcell responses can also be used as a measure
of recent exposure of the immune system to viral proteins. In
this assay, total PBMCs are exposed to HIV-1 peptides and
intramolecular staining for known cytokines is used to deter-
mine whether CD4 and CD8 T cells are responsive to HIV. A
decline of T cell specificity for HIV-1 peptides indicates that
the immune system has not been exposed to antigen recently.
However, a recent study by Oleson et al. found that in their
study group, cytokine expression was not correlated with
levels of HIV DNA; however, they did find that the frequency
of natural killer cells was inversely correlated with levels of
HIV DNA in infected individuals [56]. In addition to the re-
sponse of T cells, cell surface proteins that correlate with cell
activation are biomarkers that may be useful to predict reser-
voir size. Levels of HIV-1 proviral DNA are significantly
correlated with markers of cell activation with the strongest
association being observed between HIV-1 proviral DNA and
the markers PD-1 and HLA-DR [57, 58]. Therefore, PD-1 and
HLA-DR expression could also potentially be used as a alter-
nate markers for the presence of residual HIV-1.
One common feature of all the assays that have been
discussed above is that they all are largely used and optimized
in peripheral blood samples. However, the lymph node and
gut-associated lymph node tissues are also well-known reser-
voirs of persistent HIV. As stated above, an ideal assay would
use a small blood sample and provide a prediction of the total
pool of persistent HIV. However, to determine whether an
assay is a good predictor of the total reservoir, it is important
to have a thorough understanding of howmuch persistent HIV
is in each tissue reservoir. RNA/DNAscope (NAscope) was
developed by Jacob Estes to detect HIV-1 RNA and DNA in
tissue specimens [59]. NAScope is a modified version of tra-
ditional in-situ hybridization that is more specific allowing
individually infected cells to be detected and quantitated.
The PCR-based methods discussed above as well as tradition-
al in-situ hybridization techniques have also been used to
detect HIV-1 in tissue samples [54••, 60–63]. Sequencing
can also be used to characterize persistent reservoirs in tissue
samples and compare them to the peripheral blood compo-
nents. Sequencing studies of the lymph nodes and gut-
associated lymph node tissues have largely showed that these
populations intermingle with HIV populations from the
peripheral blood indicating that HIV-1 regularly traffics be-
tween these compartments [16]. Analysis of the cerebral spi-
nal fluid in some individuals does indicate that compartmen-
talization can occur across the blood brain barrier [64]. As
new curative strategies progress from the initial phases, it will
be crucial that the reservoirs in the tissue compartment be
quantifiable so that the effects of new strategies can be
measured.
ART treatment interruption is the ultimate measure of
whether replication competent virus persists. Many have res-
ervations about using treatment interruption as lack of ART
adherence and treatment interruptions has been shown to cor-
relate with poorer health outcomes for the patients [65, 66].
However, these studies were not designed to closely monitor
participants and place them back on ART as is proposed for
the analytical treatment interruptions to test the efficacy of
curative/remission strategies. Additional studies need to be
conducted to determine the full effects of well-controlled an-
alytical treatment interruptions and whether the participants
are significantly negatively affected.
A functional cure in which all replication competent virus
is eliminated is the ultimate goal of HIV-1 research. However,
recent studies have indicated that decreasing the HIV-1
reservoir by several folds may be sufficient to effect HIV-1
remission during which HIV-1 infected individuals could stop
taking therapy for months or years without recurrent viremia.
The Davenport lab analyzed the results from four cohorts and
a total of 100 participants who underwent treatment interrup-
tion and determined that on average, a new virus reactivates
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every five to eight days [67•]. Furthermore, based on this
number, they estimate that a 50–70-fold reduction in the viral
reservoir would be needed to achieve HIV-1 remission for
approximately one year, which is less than the 2000-fold re-
duction that was previously estimated [67•, 68]. Most of the
assays that are currently being used to estimate the latent res-
ervoir are close to the limit of detection with the current levels
of persistent HIV-1 in participants on long-term effective ther-
apy. To be able to detect a 50–70-fold reduction in these
levels, significantly more sensitive assays and technologies
will need to be developed.
Eriksson et al. compared some of the most common
assays that are used to measure the latent reservoir in-
cluding qPCR and ddPCR for HIV-1 DNA, Alu PCR for
integrated HIV-1 DNA, DNA and RNA in the gut-
associated lymphoid tissue, ddPCR for 2-LTR circles,
and the single-copy assay, and compared them to results
from the same study participants using the viral out-
growth assay [69••]. None of the measurements from
the techniques studied were strongly correlated with the
results from the viral outgrowth assay, which is not sur-
prising given that each assay measures very different
aspects of HIV-1 replication that may expand or contract
independently (Fig. 1). Additionally, Chun et al. com-
pared HIV-1 DNA to plasma viremia and markers of
immune activation and found a correlation between plas-
ma viremia and cell-associated DNA, but did not observe
a significant correlation when they compared cell-
associated DNA to markers of immune activation [41].
These studies highlight the fact that with the currently
available technologies, the results from multiple methods
may need to be combined to predict a confident estimate
of the size of the reservoir.
In addition to these studies, a large collaboration between
several different labs using most of the current techniques
available with a large range of anatomical samples attempted
to detect HIV-1 in the longest case of HIV-1 remission cur-
rently known as the Berlin patient [54••]. HIV-1 RNA/DNA
was detected at very low levels in three independent labs;
however, to date, no viral rebound has occurred. In contrast,
a similar study was performed on two participants who re-
ceived bone marrow transplants in which no virus was detect-
ed by any of the methods used. However, both of these indi-
viduals experienced rebound following treatment interruption
[53••]. These two studies highlight the difficulty of accurately
measuring the latent reservoir.
Conclusions
In conclusion, many innovative and sensitive assays are avail-
able to measure and predict the size of the persistent reservoir
in HIV-1-infected individuals on long-term suppressive ther-
apy. Despite some limitations for each assay, combining these
techniques may provide a powerful estimation of the latent
reservoir. A clear understanding of each assay and how to
interpret the information provided is critical for translating
the findings into meaningful recommendations for patients.
Even with the best and most careful measurements, it is likely
that well-monitored analytical treatment interruptions will
provide the most significant insights into the effectiveness of
cure and remission studies.
Fig. 1 The many different stages
of the HIV replication cycle and
the response of the host’s immune
system can be detected with
sensitive assays to quantitate HIV
in HIV-infected individuals on
effective long-term antiretroviral
therapy
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